This inventor holds 1 USPTO granted patent. Top assignees: Chugai Seiyaku Kabushiki Kaisha, Hiroshima University, Tokyo Women's Medical University. Active years: 2026.
Company Filing History:
1 out of 984 
1 out of 258 
1 out of 42 
Years Active: 2026
Title: Kohei Kobatake: Innovator in Urological Cancer Treatment
Introduction
Kohei Kobatake is a prominent inventor based in Hiroshima, Japan. He has made significant contributions to the field of medical science, particularly in the treatment of urological cancers. His innovative approach combines various therapeutic agents to enhance treatment efficacy.
Latest Patents
Kohei Kobatake holds a patent for a therapeutic agent aimed at treating urological cancer. This patent, characterized by the administration of an IL-6 inhibitor and a CCR2 inhibitor in combination, focuses on therapeutic agents and treatment methods for urologic cancers. These methods are particularly relevant for cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function. The agents and methods provided in the patent are designed to suppress both IL-6 activity and CCR2/CCL2 activity.
Career Highlights
Throughout his career, Kohei Kobatake has worked with esteemed institutions such as Tokyo Women's Medical University and Hiroshima University. His research and innovations have significantly impacted the medical community, particularly in the area of cancer treatment.
Collaborations
Kohei Kobatake has collaborated with various professionals in his field, including his coworker Hiroaki Honda. These collaborations have furthered research and development in therapeutic methods for urological cancers.
Conclusion
Kohei Kobatake's contributions to the field of urological cancer treatment through his innovative patent demonstrate his commitment to advancing medical science. His work continues to inspire future research and development in this critical area of healthcare.